In a report released on December 17, Emily Bodnar from H.C. Wainwright maintained a Buy rating on SAB Biotherapeutics, with a price target of $9.00.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Emily Bodnar has given his Buy rating due to a combination of factors related to SAB-142’s clinical profile and development path. She emphasizes that the final Phase 1 single- and multiple-ascending dose data show SAB-142 to be generally well tolerated across healthy volunteers, re-dosed individuals, and type 1 diabetes (T1D) patients, with no occurrences of serum sickness or adverse events tied to anti-drug antibodies. The transient and reversible lymphopenia observed in all participants confirms pharmacodynamic activity while normalizing to placebo levels by 6–12 months, supporting a safety and target-engagement profile suitable for chronic redosing. Bodnar views this as a key differentiation from existing lymphodepleting agents like rabbit anti-thymocyte globulin, which can cause longer-lasting lymphodepletion and higher rates of immune-related toxicities.
Bodnar also highlights that the fully human nature of SAB-142 appears to overcome the immunogenicity challenges associated with animal-derived globulins, further strengthening its potential for long-term use in T1D. The ongoing, registrational Phase 2b SAFEGUARD trial, with a robust, global, randomized, double-blind, placebo-controlled design in newly diagnosed Stage 3 T1D patients, provides a clear late-stage development path and catalyst roadmap. The primary endpoint, C-peptide preservation after one year, mirrors a prior successful trial of a related mechanism, bolstering confidence in potential efficacy. Combining the favorable safety/immunogenicity data, the differentiated mechanism with chronic-use potential, and the de-risked, pivotal trial design, she concludes that the risk/reward profile supports a Buy rating on SAB Biotherapeutics’ shares.
In another report released today, Guggenheim also initiated coverage with a Buy rating on the stock with a $15.00 price target.
SABS’s price has also changed dramatically for the past six months – from $1.780 to $3.960, which is a 122.47% increase.